Videos
Chemotherapy De-escalation for HER2-Positive Early Breast Cancer
3-Year Invasive Disease-Free Survival Results From the PHERGain Trial
3-Year Invasive Disease-Free Survival Results From the PHERGain Trial
06/21/2023
Javier Cortes, MD, PhD, International Breast Cancer Center, Madrid, Spain, discusses results from the PHERGain study, evaluating chemotherapy de-escalation strategies in HER2-positive early breast cancer, presented at the 2023 ASCO Annual Meeting.
Source:
Cortes J, Pérez-García JM, Ruiz Borrego M, et al. 3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC). Presented at 2023 ASCO Annual Meeting; June 2-6, 2023; Chicago, IL. Abstract LBA506